Skip to main content
Equibles

ACADIAN ASSET MANAGEMENT LLC

Position in DSGN — Design Therapeutics, Inc.

CIK 916542 Boston, MA
Back to DSGN Full portfolio

Position in DSGN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$7,777,321
+$1,217,964 QoQ
Shares Held
537,479
-12.8% QoQ
Ownership
0.859%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#22
of 136 holders
Holding Since
Dec 2022
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in DSGN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ACADIAN ASSET MANAGEMENT LLC holds $732,389,014 across 168 Biotechnology names. DSGN ranks #23 (1.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INCY
Incyte Corp
 1,664,999 $188,744,286
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,440 $98,170,137
3 IMCR
Immunocore Holdings plc
 1,209,894 $38,414,134
4 RIGL
Rigel Pharmaceuticals Inc
 591,686 $23,146,756
5 EXEL
Exelixis, Inc.
 421,444 $22,930,768
6 VRTX
Vertex Pharmaceuticals Inc / Ma
 42,122 $20,923,261
7 TBPH
Theravance Biopharma, Inc.
 1,174,910 $19,973,470
8 PRTA
Prothena Corp Public Ltd Co
 2,010,645 $19,684,214

All Filings in DSGN

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,777,321 537,479
2026-03-31 $6,559,357 616,481
2025-12-31 $5,747,763 612,768
2025-09-30 $4,649,692 617,489
2025-06-30 $2,114,162 627,348
2025-03-31 $2,435,478 630,953
2024-12-31 $3,502,116 567,604
2024-09-30 $3,137,400 583,160
2024-06-30 $1,953,586 583,160
2024-03-31 $1,626,290 403,546
2023-12-31 $478,963 180,741
2022-12-31 $594,638 57,957